FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323654893> ?p ?o ?g. }

• W4323654893 endingPage "102202" @default.
• W4323654893 startingPage "102202" @default.
• W4323654893 abstract "Pulmonary fibrosis is a chronic interstitial fibrosis lung disease with high mortality, which is often complicated with lung cancer. The incidence of IPF complicated with lung cancer is getting higher and higher. At present, there is no consensus on the management and treatment of pulmonary fibrosis patients with lung cancer. There is an urgent need to develop preclinical drug evaluation methods for IPF with lung cancer and potential therapeutic drugs for IPF with lung cancer. The pathogenic mechanism of IPF is similar to that of lung cancer, and the multi-effect drugs with anticancer and anti-fibrosis will have potential value in the treatment of IPF complicated with lung cancer. In this study, we established an animal model of IPF complicated with lung cancer in situ to evaluate the therapeutic effect of the antiangiogenic drug anlotinib. The pharmacodynamic results in vivo showed that anlotinib could significantly improve the lung function of IPF-LC mice, reduce the content of collagen in lung tissue, increase the survival rate of mice, and inhibit the growth of lung tumor in mice. The results of Western blot and immunohistochemical analysis of lung tissue showed that anlotinib significantly inhibited the expression of fibrosis marker protein α-SMA, Collagen I and Fibronectin and tumor proliferation marker protein PCNA in mouse lung tissue, and down-regulated the content of serum tumor marker CEA. Through transcriptome analysis, we found that anlotinib regulates MAPK signal pathway, PARP signal pathway and coagulation cascade signal pathway in lung cancer and pulmonary fibrosis, which all play an important role in lung cancer and pulmonary fibrosis. In addition, there is crosstalk between the signal pathway participated by the target of anlotinib and MAPK, JAK/STAT and mTOR signal pathway. In summary, anlotinib will be a candidate for IPF-LC treatment." @default.
• W4323654893 created "2023-03-10" @default.
• W4323654893 creator A5006213079 @default.
• W4323654893 creator A5037248049 @default.
• W4323654893 creator A5040109274 @default.
• W4323654893 creator A5040818050 @default.
• W4323654893 creator A5061579277 @default.
• W4323654893 creator A5085610505 @default.
• W4323654893 creator A5087153998 @default.
• W4323654893 creator A5089020338 @default.
• W4323654893 creator A5059178512 @default.
• W4323654893 date "2023-06-01" @default.
• W4323654893 modified "2023-09-30" @default.
• W4323654893 title "Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma" @default.
• W4323654893 cites W2114970103 @default.
• W4323654893 cites W2138871107 @default.
• W4323654893 cites W2573092232 @default.
• W4323654893 cites W2772453905 @default.
• W4323654893 cites W2791602004 @default.
• W4323654893 cites W2793605704 @default.
• W4323654893 cites W2810290331 @default.
• W4323654893 cites W2891433314 @default.
• W4323654893 cites W2925034291 @default.
• W4323654893 cites W2948884937 @default.
• W4323654893 cites W2971351106 @default.
• W4323654893 cites W2982700377 @default.
• W4323654893 cites W3015380548 @default.
• W4323654893 cites W3039349167 @default.
• W4323654893 cites W3041660192 @default.
• W4323654893 cites W3083040024 @default.
• W4323654893 cites W3136644565 @default.
• W4323654893 cites W3139313328 @default.
• W4323654893 cites W3170062924 @default.
• W4323654893 cites W4206220681 @default.
• W4323654893 cites W4229440424 @default.
• W4323654893 cites W4281289615 @default.
• W4323654893 doi "https://doi.org/10.1016/j.pupt.2023.102202" @default.
• W4323654893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36906117" @default.
• W4323654893 hasPublicationYear "2023" @default.
• W4323654893 type Work @default.
• W4323654893 citedByCount "0" @default.
• W4323654893 crossrefType "journal-article" @default.
• W4323654893 hasAuthorship W4323654893A5006213079 @default.
• W4323654893 hasAuthorship W4323654893A5037248049 @default.
• W4323654893 hasAuthorship W4323654893A5040109274 @default.
• W4323654893 hasAuthorship W4323654893A5040818050 @default.
• W4323654893 hasAuthorship W4323654893A5059178512 @default.
• W4323654893 hasAuthorship W4323654893A5061579277 @default.
• W4323654893 hasAuthorship W4323654893A5085610505 @default.
• W4323654893 hasAuthorship W4323654893A5087153998 @default.
• W4323654893 hasAuthorship W4323654893A5089020338 @default.
• W4323654893 hasConcept C126322002 @default.
• W4323654893 hasConcept C142724271 @default.
• W4323654893 hasConcept C2776256026 @default.
• W4323654893 hasConcept C2777714996 @default.
• W4323654893 hasConcept C2778341716 @default.
• W4323654893 hasConcept C2778807442 @default.
• W4323654893 hasConcept C2781244666 @default.
• W4323654893 hasConcept C502942594 @default.
• W4323654893 hasConcept C71924100 @default.
• W4323654893 hasConceptScore W4323654893C126322002 @default.
• W4323654893 hasConceptScore W4323654893C142724271 @default.
• W4323654893 hasConceptScore W4323654893C2776256026 @default.
• W4323654893 hasConceptScore W4323654893C2777714996 @default.
• W4323654893 hasConceptScore W4323654893C2778341716 @default.
• W4323654893 hasConceptScore W4323654893C2778807442 @default.
• W4323654893 hasConceptScore W4323654893C2781244666 @default.
• W4323654893 hasConceptScore W4323654893C502942594 @default.
• W4323654893 hasConceptScore W4323654893C71924100 @default.
• W4323654893 hasLocation W43236548931 @default.
• W4323654893 hasLocation W43236548932 @default.
• W4323654893 hasOpenAccess W4323654893 @default.
• W4323654893 hasPrimaryLocation W43236548931 @default.
• W4323654893 hasRelatedWork W1976233355 @default.
• W4323654893 hasRelatedWork W1981925459 @default.
• W4323654893 hasRelatedWork W2015980175 @default.
• W4323654893 hasRelatedWork W2172998173 @default.
• W4323654893 hasRelatedWork W2407252227 @default.
• W4323654893 hasRelatedWork W2472837931 @default.
• W4323654893 hasRelatedWork W2522898898 @default.
• W4323654893 hasRelatedWork W3142039466 @default.
• W4323654893 hasRelatedWork W4247412979 @default.
• W4323654893 hasRelatedWork W4323654893 @default.
• W4323654893 hasVolume "80" @default.
• W4323654893 isParatext "false" @default.
• W4323654893 isRetracted "false" @default.
• W4323654893 workType "article" @default.